tirzepatide negatives People using drug Mounjaro sustain weight loss over three years, trial finds | Obesity Mounjaro, Zepbound Lowers Risk of

Prospective study showing residual gastric solids in volunteers on GLP-1 receptor agonists despite adequate fasting

If you are like me and have tried everything, then I hope you find the article helpful

In published research, tirzepatide has demonstrated superior glycemic and body-weight effects compared with selective GLP-1 agonists in head-to-head studies

Tirzepatide was studied at up to 5 mg weekly

The program theoretically will expire at the end of 2027, although those taking GLP-1 drugs for obesity at that point are likely to advocate for its continuation

But the direction is consistent across sources: of the GLP-1 medications, semaglutide is the one most associated with constipation